Sign in

CIK 0001740279

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

IN8BIO, INC.

Sign in to watch
Ticker
INAB
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
825462585
Phone
+1 646-600-6438
Business address
EMPIRE STATE BUILDING, 350 5TH AVENUE, SUITE 5330, NEW YORK, NY, 10118
Former names
Incysus Therapeutics, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2026-05-09 Rochlin Kate President and COO Grant or award · Employee Stock Option (right to buy) +60,000 60,000
2026-02-04 Rochlin Kate President and COO Grant or award · Employee Stock Option (right to buy) +80,000 80,000
2025-12-22 Rochlin Kate Chief Operating Officer Grant or award +7,247 $1.38 $10K 9,085
2025-04-30 Rochlin Kate Chief Operating Officer Option exercise +12,295 $0.18 $2K 55,169
2025-04-30 Rochlin Kate Chief Operating Officer Option exercise · Series A Warrants (right to buy) −12,295 0
2025-04-27 Rochlin Kate Chief Operating Officer Returned to the company · Series A Warrants (right to buy) −12,295 0
2025-04-27 Rochlin Kate Chief Operating Officer Grant or award · Series A Warrants (right to buy) +12,295 12,295
2025-04-27 Rochlin Kate Chief Operating Officer Returned to the company · Series B Warrants (right to buy) −12,295 0
2025-04-27 Rochlin Kate Chief Operating Officer Grant or award · Series B Warrants (right to buy) +12,295 12,295
2025-02-05 Rochlin Kate Chief Operating Officer Grant or award · Employee Stock Option (right to buy) +338,950 338,950
2024-12-19 Rochlin Kate Chief Operating Officer Grant or award · Employee Stock Option (right to buy) +302,839 302,839
2024-10-04 Rochlin Kate Chief Operating Officer Grant or award +25,316 42,874
2024-10-04 Rochlin Kate Chief Operating Officer Returned to the company · Series A Warrants (right to buy) −12,295 0
2024-10-04 Rochlin Kate Chief Operating Officer Grant or award · Series A Warrants (right to buy) +12,295 12,295
2024-10-04 Rochlin Kate Chief Operating Officer Grant or award · Series C Warrants (right to buy) +25,316 25,316
2024-09-04 Rochlin Kate Chief Operating Officer Grant or award · Employee Stock Option (right to buy) +250,000 250,000
2024-02-07 Rochlin Kate CHIEF OPERATING OFFICER Grant or award · Employee Stock Option (right to buy) +186,000 186,000
2023-12-13 Rochlin Kate Chief Operating Officer Grant or award +12,295 17,558
2023-12-13 Rochlin Kate Chief Operating Officer Grant or award · Series A Warrants (right to buy) +12,295 12,295
2023-12-13 Rochlin Kate Chief Operating Officer Grant or award · Series B Warrants (right to buy) +12,295 12,295

Page 1 of 2 · 25 trades